RxSight price target raised to $10 from $8 at Stifel

Stifel raised the firm’s price target on RxSight (RXST) to $10 from $8 and keeps a Hold rating on the shares. The quarter was better than feared, with revenue of $30M strongly above the firm’s and Wall Street’s estimates, the analyst tells investors in a research note. The firm added that it senses the Street’s $134M 2026 revenue estimate is in a comfortable place.